Floatz logo

Satraplatin

Hormone Refractory Prostate Cancer

AgennixSmall moleculePhase 3Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Hormone Refractory Prostate Cancer cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
at-101
Ascenta Therapeutics
Phase 2BB
RADIUM RA-223
Bayer
Phase 3BB
Docetaxel
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
Denosumab
Amgen
Phase 3B

View all 43 →

Same molecule, other indications

Satraplatin is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
prostate cancerDormant
CCC
Indicative ·
54 / 100
View asset →
disease of genetic or genomic mechanismDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →